SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Micrologix biotech
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Carter Berezay who wrote (591)10/18/1999 10:06:00 AM
From: Sean Janzen  Read Replies (1) of 792
 
Here's an old article, May 99, from PENCE:
nce.nserc.ca

I found the following paragraph particularly interesting. I was unaware that MBI was working on a TB drug.

"In particular, Micrologix is targeting the improved compounds at drug-resistant bacteria such as Staphylococcus aureus and Mycobacterium tuberculosis. S. aureus is the difficult-to-treat bacterium responsible for a range of infections including pneumonia. M. tuberculosis is the untreatable cause of tuberculosis, a disease that is presently re-emerging in many countries and killed approximately 3 million people in 1997 alone."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News